{"title":"阿巴美匹尔：一个古老问题的新解决方案。","authors":"Atreyo Chakraborty","doi":"10.4103/ijt.ijt_77_22","DOIUrl":null,"url":null,"abstract":"<p><p>Abametapir is a new metalloproteinase inhibitor that received Food and Drug Administration approval in July 2020 as a topical pediculocide. The uniqueness of this new drug is that it targets metalloproteinase needed for hatching the eggs as well as killing adults. Herein we discuss this new drug, its history of development, its modality of use and its adverse drug reactions. It is hoped it will make Dermatologists aware of this new development.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"16 1-6","pages":"55-57"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039782/pdf/","citationCount":"0","resultStr":"{\"title\":\"Abametapir: A New Solution to an Age Old Problem.\",\"authors\":\"Atreyo Chakraborty\",\"doi\":\"10.4103/ijt.ijt_77_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Abametapir is a new metalloproteinase inhibitor that received Food and Drug Administration approval in July 2020 as a topical pediculocide. The uniqueness of this new drug is that it targets metalloproteinase needed for hatching the eggs as well as killing adults. Herein we discuss this new drug, its history of development, its modality of use and its adverse drug reactions. It is hoped it will make Dermatologists aware of this new development.</p>\",\"PeriodicalId\":14417,\"journal\":{\"name\":\"International Journal of Trichology\",\"volume\":\"16 1-6\",\"pages\":\"55-57\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039782/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Trichology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijt.ijt_77_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Trichology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijt.ijt_77_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Abametapir is a new metalloproteinase inhibitor that received Food and Drug Administration approval in July 2020 as a topical pediculocide. The uniqueness of this new drug is that it targets metalloproteinase needed for hatching the eggs as well as killing adults. Herein we discuss this new drug, its history of development, its modality of use and its adverse drug reactions. It is hoped it will make Dermatologists aware of this new development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
